/AKTX
AKTX Stock - Akari Therapeutics, Plc
Healthcare|BiotechnologyNASDAQ
$0.26+6.16%
+$0.02 (+6.16%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+11434.0%upside
Target: $30.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AKTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.26 – $0.26
TARGET (TP)$30.00
STOP LOSS$0.24
RISK/REWARD1:1479.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.28
52W High$1.73
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-21,643,000 | $-16,806,000 | $-23,088,000 | $-17,214,136 | $-17,980,974 |
| Net Income | $-19,791,000 | $-10,008,000 | $-17,748,000 | $-17,424,237 | $-17,081,617 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1660.00 | $-200.00 | $-220.00 | $-820.00 | $-1560.00 |
Company Overview
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 1822.3% Upside
Now
$5
Low
$5
Average
$5
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 18th 2025 | Maxim Group | Initiation | Buy | $5 |
Earnings History & Surprises
AKTXBeat Rate
75%
Last 8 quarters
Avg Surprise
-6086300.9%
EPS vs Estimate
Beats / Misses
6/2
Last 12 quarters
Latest EPS
$-19476.29
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
+100.0%
$-0.00vs$-1.00
Q3 24
+100.0%
$-0.00vs$-1.00
Q4 24
+100.0%
$-0.00vs$-0.60
Q1 25
No data
Q2 25
-578.7%
$-6.79vs$-1.00
Q3 25
No data
Q4 25
-48690628.2%
$-19476.29vs$-0.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.04 | $-19476.29 | -48690628.2% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | — | $-120.42 | — | — |
Q2 2025 | Apr 16, 2025 | $-1.00 | $-6.79 | -578.7% | ✗ MISS |
Q1 2025 | Mar 28, 2025 | — | $-0.16 | — | — |
Q4 2024 | Nov 19, 2024 | $-0.60 | $-0.00 | +100.0% | ✓ BEAT |
Q3 2024 | Aug 19, 2024 | $-1.00 | $-0.00 | +100.0% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-1.00 | $-0.00 | +100.0% | ✓ BEAT |
Q1 2024 | Mar 29, 2024 | — | $-0.00 | — | — |
Q4 2023 | Oct 3, 2023 | $-0.60 | $-0.00 | +99.9% | ✓ BEAT |
Q3 2023 | Sep 26, 2023 | $-1.00 | $2.00 | +300.0% | ✓ BEAT |
Q2 2023 | May 1, 2023 | $-0.07 | $0.00 | +100.2% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 9, 2023 | — | $-0.00 | — | — |
Q3 2022 | Jul 20, 2022 | — | $-2.00 | — | — |
Q2 2022 | May 17, 2022 | — | $-0.00 | — | — |
Q2 2022 | May 16, 2022 | — | $-2.40 | — | — |
Q4 2021 | Dec 3, 2021 | — | $-0.60 | — | — |
Q3 2021 | Sep 22, 2021 | — | $-2.20 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-3.00 | — | — |
Latest News
Akari Therapeutics shares are trading lower after the company announced a registered direct offering and private placement for the $5 million.
📉 NegativeBenzinga•Dec 16, 2025, 03:42 PM
Akari Therapeutics To Issue ~12.6M ADSs And Series G Warrants At $0.3883–$0.4041, Raising Gross Process Of ~$5M
➖ NeutralBenzinga•Dec 16, 2025, 02:31 PM
Akari Therapeutics Reports Its AKTX-101 Shows Potent Preclinical Activity Against K-Ras G12V Pancreatic Cancer Cells
📈 PositiveBenzinga•Dec 9, 2025, 01:41 PM
Akari Therapeutics Appoints Kameel D. Farag As Interim Chief Financial Officer
➖ NeutralBenzinga•Nov 18, 2025, 01:41 PM
Akari Therapeutics Data On PH1 ADC Payload Shows Ability To Induce Both Cancer Cell Cytotoxicity, Activation Of Anti-tumor Immunity With Multiple Mechanisms
📈 PositiveBenzinga•Nov 10, 2025, 01:46 PM
Akari Therapeutics Appoints Kameel Farag As Interim CFO
➖ NeutralBenzinga•Oct 23, 2025, 08:51 PM
Akari Therapeutics shares are trading lower after the company announced a $2.5 million registered direct offering of 3.125 million American Depositary Shares at $0.80 per ADS.
📉 NegativeBenzinga•Oct 15, 2025, 02:54 PM
Akari Therapeutics Announces A $2.5M Registered Direct Offering Of 3,125,000 American Depositary Shares At $0.80 Per ADS
➖ NeutralBenzinga•Oct 15, 2025, 12:37 PM
Akari Therapeutics Files Two U.S. Provisional Patents For PH1 Payload And Combination ADC Therapy Targeting Immune Activation And Checkpoint Synergy
📈 PositiveBenzinga•Oct 9, 2025, 12:48 PM
Akari Therapeutics To Present Splicing-Targeted ADC Data At SITC 2025, Highlighting Immune Activation And Checkpoint Synergy In Oral And Poster Sessions
📈 PositiveBenzinga•Oct 3, 2025, 01:34 PM
Akari Therapeutics Announces Preclinical Data Supporting PH1 Spliceosome-Modulating ADC For AR-V7–Driven Prostate Cancer
📈 PositiveBenzinga•Sep 24, 2025, 12:48 PM
AKTX stock has given up its prior loss. Akari Therapeutics shares were trading lower.
➖ NeutralBenzinga•Sep 17, 2025, 03:30 PM
Akari Therapeutics shares are trading lower. The company announced that it has filed a provisional patent application with the United States Patent and Trademark Office covering the its antibody drug conjugate platform using its spliceosome payload PH1 for treating cancer by modulating alternative splicing within cancer cells.
📉 NegativeBenzinga•Sep 17, 2025, 01:18 PM
Akari Therapeutics Files Provisional Patent Application With USPTO Covering ADC Platform Using Akari's Spliceosome Payload PH1 For Treating Cancer By Modulating Alternative Splicing Within Cancer Cells
📈 PositiveBenzinga•Sep 17, 2025, 12:53 PM
HC Wainwright & Co. Reiterates Buy on Akari Therapeutics, Maintains $1.6 Price Target
📈 PositiveBenzinga•Sep 9, 2025, 10:29 AM
Akari Therapeutics shares are trading lower after the company announced it entered into an ordinary share purchase agreement with White Lion Capital.
📉 NegativeBenzinga•Sep 2, 2025, 04:01 PM
Akari Therapeutics Enters Ordinary Share Purchase Agreement With White Lion Capital; Can Sell Up To $25M Of Shares
📈 PositiveBenzinga•Aug 29, 2025, 09:16 PM
Frequently Asked Questions about AKTX
What is AKTX's current stock price?
Akari Therapeutics, Plc (AKTX) is currently trading at $0.26 per share. The stock has moved +6.16% today.
What is the analyst price target for AKTX?
The average analyst price target for AKTX is $30.00, based on 1 analyst.
What sector is Akari Therapeutics, Plc in?
Akari Therapeutics, Plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AKTX's market cap?
Akari Therapeutics, Plc has a market capitalization of $0.00 billion, making it a small-cap company.
Does AKTX pay dividends?
No, Akari Therapeutics, Plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCDT
CDT Equity Inc.
$1.63
Mkt Cap: $0.0B
DRMA
Dermata Therapeutics, Inc.
$2.14
Mkt Cap: $0.0B
MSPR
MSP Recovery, Inc.
$0.20
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
PPBT
Purple Biotech Ltd.
$0.71
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SYRS
Syros Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
VINC
Vincerx Pharma, Inc.
$0.01
Mkt Cap: $0.0B
VRPX
Virpax Pharmaceuticals, Inc.
$0.02
Mkt Cap: $0.0B
XAGE
Longevity Health Holdings Inc.
$0.43
Mkt Cap: $0.0B
Explore stocks similar to AKTX for comparison